Improvement of hematopoietic stem cell transplantation in the targeted therapy era

Hematopoietic stem cell transplantation (HSCT) is one of best ways to treat hematological malignancies. And, allogeneic HSCT has been developing rapidly in our country within recent decades, and accomplished many transplantation schemes and technological systems with Chinese characteristics. Especi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	ZHANG Xi, HUANG Ruihao
Formato:	article
Lenguaje:	ZH
Publicado:	Editorial Office of Journal of Third Military Medical University 2021
Materias:	allogeneic hematopoietic stem cell transplantation hematologic neoplasms car-t cell therapy targeted therapy Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b476ded08c7b4a99b6cbe6ad6f890186
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b476ded08c7b4a99b6cbe6ad6f890186
record_format	dspace
spelling	oai:doaj.org-article:b476ded08c7b4a99b6cbe6ad6f8901862021-11-12T04:19:28ZImprovement of hematopoietic stem cell transplantation in the targeted therapy era10.16016/j.1000-5404.2021081541000-5404https://doaj.org/article/b476ded08c7b4a99b6cbe6ad6f8901862021-11-01T00:00:00Zhttp://aammt.tmmu.edu.cn/Upload/rhtml/202108154.htmhttps://doaj.org/toc/1000-5404 Hematopoietic stem cell transplantation (HSCT) is one of best ways to treat hematological malignancies. And, allogeneic HSCT has been developing rapidly in our country within recent decades, and accomplished many transplantation schemes and technological systems with Chinese characteristics. Especially, the mature application of haplo-identical HSCT promotes the transplantation into an era of "everyone has a donor". Nowadays, constantly emerged epigenetic regulators, pathway modulators of leukemia genesis and immune cell therapies have provided more options for physician and patients so far in HSCT. In this article, we summarize the application of new drugs in the whole process of allogeneic HSCT (before, during and after transplantation) and related new technologies and new schemes. We consider that the closer combination of new drugs such as targeted drugs and HSCT is an effective measure to further improve the efficacy and safety of allogeneic HSCT. We should organically integrate the existing technologies and new drugs into the best scheme in order to further enhance the efficacy and improve the quality of life of patients. This is a problem that must be focused on in this field in the future.ZHANG XiHUANG Ruihao Editorial Office of Journal of Third Military Medical Universityarticleallogeneic hematopoietic stem cell transplantationhematologic neoplasmscar-t cell therapytargeted therapyMedicine (General)R5-920ZHDi-san junyi daxue xuebao, Vol 43, Iss 21, Pp 2271-2275 (2021)
institution	DOAJ
collection	DOAJ
language	ZH
topic	allogeneic hematopoietic stem cell transplantation hematologic neoplasms car-t cell therapy targeted therapy Medicine (General) R5-920
spellingShingle	allogeneic hematopoietic stem cell transplantation hematologic neoplasms car-t cell therapy targeted therapy Medicine (General) R5-920 ZHANG Xi HUANG Ruihao Improvement of hematopoietic stem cell transplantation in the targeted therapy era
description	Hematopoietic stem cell transplantation (HSCT) is one of best ways to treat hematological malignancies. And, allogeneic HSCT has been developing rapidly in our country within recent decades, and accomplished many transplantation schemes and technological systems with Chinese characteristics. Especially, the mature application of haplo-identical HSCT promotes the transplantation into an era of "everyone has a donor". Nowadays, constantly emerged epigenetic regulators, pathway modulators of leukemia genesis and immune cell therapies have provided more options for physician and patients so far in HSCT. In this article, we summarize the application of new drugs in the whole process of allogeneic HSCT (before, during and after transplantation) and related new technologies and new schemes. We consider that the closer combination of new drugs such as targeted drugs and HSCT is an effective measure to further improve the efficacy and safety of allogeneic HSCT. We should organically integrate the existing technologies and new drugs into the best scheme in order to further enhance the efficacy and improve the quality of life of patients. This is a problem that must be focused on in this field in the future.
format	article
author	ZHANG Xi HUANG Ruihao
author_facet	ZHANG Xi HUANG Ruihao
author_sort	ZHANG Xi
title	Improvement of hematopoietic stem cell transplantation in the targeted therapy era
title_short	Improvement of hematopoietic stem cell transplantation in the targeted therapy era
title_full	Improvement of hematopoietic stem cell transplantation in the targeted therapy era
title_fullStr	Improvement of hematopoietic stem cell transplantation in the targeted therapy era
title_full_unstemmed	Improvement of hematopoietic stem cell transplantation in the targeted therapy era
title_sort	improvement of hematopoietic stem cell transplantation in the targeted therapy era
publisher	Editorial Office of Journal of Third Military Medical University
publishDate	2021
url	https://doaj.org/article/b476ded08c7b4a99b6cbe6ad6f890186
work_keys_str_mv	AT zhangxi improvementofhematopoieticstemcelltransplantationinthetargetedtherapyera AT huangruihao improvementofhematopoieticstemcelltransplantationinthetargetedtherapyera
_version_	1718431311053455360

Improvement of hematopoietic stem cell transplantation in the targeted therapy era

Ejemplares similares